Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis

H.Y. Cao¹*, S. Yang²*, S. Wang³, L.Y. Deng¹ and J.Y. Lou¹

¹Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
²Laboratory of Lung Development and Disease West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China
³Key Labatory of Birth and Related Diseases of Women and Children, Sichuan University Ministry of Education, Chengdu, Sichuan Province, China

*These authors contributed equally to this study.
Corresponding author: J.Y. Lou
E-mail: loujiangyan2@163.com

ABSTRACT. We conducted a meta-analysis to examine p16INK4a expression in uterine smooth muscle tumors (USMTs). Although the prognostic value of tumor suppressor p16INK4a has been elucidated in a variety of cancers and precancerous lesions, its role in USMTs is not well established. We searched PubMed, Web of Science, and Embase for publication on p16INK4a expression in USMTs. Strict inclusion and exclusion criteria were imposed. Risk ratios (RRs) with 95% confidence intervals (95%CIs) were calculated to assess the strength of association. Publication bias was estimated using funnel plots and
the Egger’s regression test. Twelve eligible studies comprising 661 patients were included. Compared with leiomyoma (LM), the figures for the strength of association were as follows: LM variants (RR = 1.53, 95%CI = 1.03-2.27, P = 0.036, random effect); leiomyosarcoma (LMS) (RR = 3.20, 95%CI = 1.68-6.12, P < 0.001, random effect); and smooth muscle tumors of uncertain malignant potential (STUMP) (RR = 2.90, 95%CI = 1.17-7.21, P = 0.022, random effect). p16INK4a expression was significantly higher in LMS than in LM variants (RR = 3.74, 95%CI = 1.96-7.13, P < 0.001, random effect) or STUMP (RR = 1.67, 95%CI = 1.26-2.23, P < 0.001, fixed effect). There was a significant correlation between overexpressed p16INK4a and recurrence rates of USMTs (RR = 1.85, 95%CI = 1.11-3.10, P = 0.019, fixed effect). p16INK4a overexpression is a potential biomarker for diagnosing problematic USMTs and it might indicate a worse prognosis. However, there is currently insufficient evidence to assess the prognostic value of p16INK4a in USMTs.

Key words: p16INK4a; Leiomyoma; Leiomyosarcoma; Meta-analysis

INTRODUCTION

Uterine smooth muscle tumors (USMTs) are the most common neoplasm in the female reproductive system. Usual leiomyoma (UM) is the most common benign tumor in the uterus, whereas malignant leiomyosarcoma (LMS) accounts for only 2.3% of uterine neoplasms (Boll et al., 2012). There are also leiomyoma (LM) variants (mitotically active, cellular, and atypical leiomyomas) that are characterized by mostly benign behavior. In some respects, LM variants have morphological similarities with LMS such as coagulative tumor cell necrosis, and the degree of cytologic atypia or mitotic activity. Finally, there are smooth muscle tumors of uncertain malignant potential (STUMP), which cannot be classified as unequivocally benign or malignant (Tavassoli and Devilee, 2003). Because of this wide range of subtypes and overlapping features, diagnostic problems still exist, despite differential diagnoses based on histopathological features, making clinical management difficult.

p16INK4a protein, encoded by the INK4A locus, inactivates the cell cycle by inhibiting cyclin-dependent kinases (CDKs) (Ruas and Peters, 1998). Loss of p16INK4a expression seems to be associated with the development and progression of cancers. The authors of previous studies have reported the diagnostic and prognostic value of overexpressed p16INK4a protein in various cancers and premalignant lesions (Sano et al., 1998; Bu et al., 2014; Huang et al., 2014; Cao et al., 2016). Although p16INK4a overexpression might be used as a surrogate marker for human papilloma virus (HPV) in cervical and vaginal carcinoma, its overexpression in other carcinomas is not necessarily related to HPV (Hellman et al., 2014). However, its diagnostic and prognostic role in USMTs remains ambiguous (Atkins et al., 2008; Mills et al., 2013). Therefore, in the present meta-analysis, which had a PICOS (population, intervention, comparators, outcomes, study) structure, we aimed to compare the level of p16INK4a expression between patients with different types of USMTs and investigate its potential prognostic value.
METHODS

Search strategy

We searched PubMed, Web of Science, and Embase databases between January 1991 and September 2016 to identify all articles that investigated the association between p16INK4a expression and USMTs. All relevant articles were retrieved using the following search terms and their combinations: “p16 or p16INK4a” and “uterine leiomyoma”, “uterine sarcoma”, “uterine leiomyosarcoma”, “uterine leiomyoma variants”, “smooth muscle tumors of uncertain malignant potential”, or “STUMP”. References in the identified publications were also screened for other relevant studies. For multiple publications including overlapping data, only the newest or largest-scale study was included. Two independent investigators first searched potentially relevant studies by screening the title and abstract, and then browsed the full texts. Any discrepancy was resolved by discussion.

Inclusion criteria

We included the following: studies in which the diagnosis of USMTs had been proven by pathological methods; studies of p16INK4a expression that were based on USMT tissue; specimens examined by immunohistochemistry; and all studies on the correlation of p16INK4a expression with USMT tissue and the association of p16INK4a overexpression with overall survival (OS) or disease-free survival (DFS), or recurrence of USMT in patients. No limitation was set on the minimum number of patients in each study for inclusion in the analysis.

Exclusion criteria

We excluded the following: review articles without original data; studies in languages other than English; studies based on serum or any other kinds of specimen; and studies using methods other than immunohistochemistry to examine specimens.

Data extraction and quality assessment

Three investigators (Hanyu Cao, Si Wang, and Liyun Deng) extracted information independently from all articles according to the inclusion criteria listed above. Any dispute was resolved by discussion until a consensus was reached between the investigators. The following information was collected from each publication: the first author’s name, the publication year, the patient’s country, the technique used, the percentage of p16INK4a-positive cells in each subtype of USMT, the number of patients, and the cut-off value of overexpression of p16INK4a in the included studies. In addition, instead of using a quality-related score system, we controlled the study quality by weighting each study with strict inclusion or exclusion criteria because there was no agreement for a standardized score system for observational studies.

Statistical analysis

The cut-off value of over expressed p16INK4a according to the stained cells is presented in Table 1 for each study. Risk ratios (RR) and 95% confidence intervals (95%CIs)
were pooled to explore whether there was a difference in p16INK4a expression between these various groups of USMTs and to evaluate the association between p16INK4a expression and patients’ survival. Heterogeneity was investigated using Cochran’s chi-square Q test with a significance level of P < 0.10 and an I^2 > 50%, the latter value representing the proportion of total variation contributed by between-study variations. In such cases, the random-effects model was applied to estimate the pooled RRs (DerSimonian and Kacker, 2007). Otherwise, the pooled RRs were estimated by the fixed-effects model. In addition, funnel plots and the Egger’s linear regression test were used to investigate publication bias (Egger and Smith, 1998). All statistical tests were carried out using Stata 12.0 software (Stata Corp, USA).

Table 1. Main characteristics of all eligible studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Patient’s country</th>
<th>Technique</th>
<th>LM</th>
<th>LM variants</th>
<th>LMS</th>
<th>STUMP</th>
<th>Number of patients</th>
<th>Cut-off (IHC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bodner-Adler</td>
<td>2005</td>
<td>Austria</td>
<td>IHC</td>
<td>3/26</td>
<td>ND</td>
<td>12/21</td>
<td>5/24</td>
<td>71</td>
<td>33%</td>
</tr>
<tr>
<td>O’Neill</td>
<td>2007</td>
<td>UK</td>
<td>IHC</td>
<td>0/10</td>
<td>7/27</td>
<td>19/22</td>
<td>1/4</td>
<td>63</td>
<td>5%</td>
</tr>
<tr>
<td>Gannon</td>
<td>2008</td>
<td>Canada</td>
<td>IHC</td>
<td>0/35</td>
<td>8/8</td>
<td>ND</td>
<td>3/8</td>
<td>46</td>
<td>66%</td>
</tr>
<tr>
<td>Chen</td>
<td>2008</td>
<td>USA</td>
<td>IHC</td>
<td>3/35</td>
<td>18/28</td>
<td>ND</td>
<td>2/2</td>
<td>100</td>
<td>25%</td>
</tr>
<tr>
<td>Atkins</td>
<td>2008</td>
<td>USA</td>
<td>IHC</td>
<td>1/15</td>
<td>ND</td>
<td>ND</td>
<td>3/8</td>
<td>46</td>
<td>66%</td>
</tr>
<tr>
<td>Ip</td>
<td>2009</td>
<td>China and Canada</td>
<td>IHC</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>2/15</td>
<td>16</td>
<td>66%</td>
</tr>
<tr>
<td>Yanai</td>
<td>2010</td>
<td>Japan</td>
<td>IHC</td>
<td>1/4</td>
<td>ND</td>
<td>2/4</td>
<td>ND</td>
<td>4</td>
<td>75%</td>
</tr>
<tr>
<td>Unver</td>
<td>2011</td>
<td>Turkey</td>
<td>IHC</td>
<td>0/15</td>
<td>1/14</td>
<td>17/21</td>
<td>1/3</td>
<td>53</td>
<td>10%</td>
</tr>
<tr>
<td>Hakverdi</td>
<td>2011</td>
<td>Turkey</td>
<td>IHC</td>
<td>0/6</td>
<td>0/9</td>
<td>5/15</td>
<td>ND</td>
<td>40</td>
<td>66%</td>
</tr>
<tr>
<td>Mills</td>
<td>2013</td>
<td>USA</td>
<td>IHC</td>
<td>ND</td>
<td>16/52</td>
<td>11/16</td>
<td>ND</td>
<td>68</td>
<td>66%</td>
</tr>
<tr>
<td>Slatter</td>
<td>2015</td>
<td>China and New Zealand</td>
<td>IHC</td>
<td>ND</td>
<td>14/24</td>
<td>6/13</td>
<td>ND</td>
<td>72</td>
<td>70%</td>
</tr>
<tr>
<td>Liang</td>
<td>2015</td>
<td>China</td>
<td>IHC</td>
<td>0/15</td>
<td>4/32</td>
<td>7/15</td>
<td>ND</td>
<td>62</td>
<td>75%</td>
</tr>
</tbody>
</table>

IHC = immunohistochemistry; LM variants = leiomyoma variants; LMS = leiomyosarcoma; ND = no data; STUMP = smooth muscle tumors of uncertain malignant potential.

RESULTS

Study inclusion and characteristics

As shown in Figure 1, a total of 12 eligible studies comprising 661 patients from different countries were included in this meta-analysis, with the number of patients ranging from 4 to 100 per study (Bodner-Adler et al., 2005; O’Neill et al., 2007; Atkins et al., 2008; Chen and Yang, 2008; Gannon et al., 2008; Ip et al., 2009; Yanai et al., 2010; Hakverdi et al., 2011; Ünver et al., 2011; Mills et al., 2013; Liang et al., 2015; Slatter et al., 2015). Nine of the studies investigated P16INK4a expression in LM, seven presented data on LM variants, ten presented data on LMS, and seven studies reported STUMP. Moreover, only four studies provided sufficient data on the association between p16INK4a and survival data. All the studies used the immune histochemical method with different cut-off values. The main characteristics of these studies are summarized in Table 1.

Differential expression of p16INK4a in USMTs

As shown in Figure 2, the overexpression of p16INK4a was significantly associated with LM variants (RR = 1.53, 95%CI = 1.03-2.27, P = 0.036, random effect; Figure 2A), LMS (RR = 3.20, 95%CI = 1.68-6.12, P < 0.001, random effect; Figure 2B), and STUMP (RR = 2.90, 95%CI = 1.17-7.21, P = 0.022, random effect; Figure 2C), compared with LM. There was a significantly higher level of p16INK4a expression in LMS than in LM variants (RR = 3.74, 95%CI = 1.96-7.13, P < 0.001, random effect; Figure 2D), or STUMP (RR = 1.67,

---

Genetics and Molecular Research 16 (1): gmr16019481
95%CI = 1.26-2.23, P < 0.001, fixed effect; Figure 2E). However, the difference in p16INK4a expression between STUMP and LM variants was not statistically significant (RR = 1.86, 95%CI = 0.50-6.93, P = 0.357, fixed effect; Figure 2F).

Figure 1. Flow chart demonstrating studies processed for inclusion in the meta-analysis.

Figure 2. Forest plots of the association between p16INK4a overexpression in leiomyoma (LM) vs LM variants (A); leiomyosarcoma (LMS) vs leiomyoma (LM) variants (B); smooth muscle tumors of uncertain malignant potential (STUMP) vs leiomyoma (LM) (C); leiomyosarcoma (LMS) vs leiomyoma (LM) variants (D); leiomyosarcoma (LMS) vs smooth muscle tumors of uncertain malignant potential (STUMP) (E); and smooth muscle tumors of uncertain malignant potential (STUMP) vs leiomyoma (LM) variants (F).
Correlation between p16INK4a expression and recurrence rates

Recurrence rates were extracted from four studies and were pooled according to the classification of USMTs using the method mentioned earlier. The association between overexpressed p16INK4a and the recurrence rates of USMTs was statistically significant (RR = 1.85, 95%CI = 1.11-3.10, P = 0.019, fixed effect; Figure 3). Subgroup analysis showed that only STUMP (RR = 3.34, 95%CI = 1.23-9.07, P = 0.018, fixed effect; Figure 3) was significantly correlated with P16INK4a, and no significant association was found between P16INK4a and LMS (RR = 1.57, 95%CI = 0.85-2.90, P = 0.148, fixed effect; Figure 3) or LM variants.

Figure 3. Forest plot for the association between p16INK4a expression and recurrence rates.

Publication bias

A Begg’s funnel plot and the Egger’s test were applied to recurrence rates to determine whether publication bias existed in the studies. The shape of the funnel plot did not show obvious asymmetry. No obvious evidence of asymmetry was found in the Egger’s test of recurrence rates (P = 0.56; Figure 4).

Figure 4. Funnel plot analysis on the detection of publication bias in the meta-analysis of the prognostic value of p16INK4a in the recurrence rates of uterine smooth muscle tumors (USMTs).
DISCUSSION

P16INK4a is a classic tumor suppressor that is encoded by the CDKN2A gene. It is able to inactivate the retinoblastoma (RB1) family of tumor suppressor proteins by inhibiting cyclin-dependent kinases CDK4 and CDK6, leading to cell-cycle arrest (Ortega et al., 2002). Various human cancers are characterized by the functional loss of the INK4a family of proteins and the over expression of p16INK4a. Such factors are significantly associated with the outcome of many malignant tumors such as cervical cancer, osteosarcoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and non-small lung cancer (Zong et al., 2012; Bu et al., 2014; Huang et al., 2014; Ndiaye et al., 2014; Huang et al., 2015). There remains a scarcity of published evidence to support the role of over expressed p16INK4a in USMTs.

Uterine LM and LMS are at opposite ends of the pathological spectrum of uterine smooth muscle tumors, with several LM variants and STUMP in between (Arleo et al., 2015). LM occurs in nearly 80% of women of reproductive age, although only 30% experience symptoms that are so severe that they are compelled to seek treatment (Moravek et al., 2015). Moreover, the identification of LM variants and STUMP currently hampers the diagnosis of USMTs, although the 2003 World Health Organization (WHO) diagnostic criteria for USMTs has distinguished some rare variants of leiomyoma (Hendrickson et al., 2003). LMS is the most malignant USMT; it is associated with a high risk of recurrence and metastasis, and a poor overall survival rate of only 10-25% (Zaloudek and Hendrickson, 2002). LMS is mainly treated by surgery that comprises total abdominal hysterectomy and bilateral salpingo-oophorectomy. No convincing evidence for the effectiveness of adjuvant radiation therapy or chemotherapy has been reported. However, some times, histopathological examination reveals that a presumptive LM uterine tumor is actually an LMS or an LM variant. This is because in many cases, imaging examination reveals no obvious signs, and no typical clinical manifestations are presented. Therefore, there is a pressing need to discover biomarkers for the early differential diagnosis of USMTs and indicators for prognosis that provide guidance for early treatment and clinical management. This study is possibly the first meta-analysis that has evaluated the diagnostic and prognostic value of p16INK4a in USMTs.

The present meta-analysis using pooled RRs demonstrated that p16INK4a overexpression correlates significantly with LMS, STUMP, and LM variants compared with LM. The classification of STUMP and LM variants is problematic owing to their unpredictable clinical course and the lack of clinical evidence (Peters et al., 1994). Atkins et al. (2008) suggested that STUMPs should be classified as LMSs, and Ip et al. (2009) and Yanai et al., (2010) concluded that patients diagnosed with STUMPs should receive long-term surveillance owing to their often delayed recurrence and low-grade malignancy behavior. However, all the patients with STUMPs in the study by Bodner-Adler et al. (2005) had favorable outcomes.

Although many previous studies have reported p16 to be a useful marker for the discrimination of LMS from other types of USMT, the difference is not very pronounced in the study by Atkins et al. (2008). Moreover, very few studies presented a recurrence rate related to p16INK4a and USMTs after repeated searches, which may have been due to the low frequency of malignant USMTs. Analysis of outcome in the present study revealed a statistically significant connection between p16INK4a overexpression and recurrence rates of USMTs, in accordance with the study by D’Angelo et al. (2011), who reported that the immunoreactions of p16 had a negative effect on disease-free survival. Both Ip et al. (2009) and Atkins et al. (2008) concluded that strong, diffuse p16 expression might help to identify the
recurrence of STUMPs, whereas Mills et al. (2013) denied the prognostic value of p16INK4a in atypical LMs.

Nevertheless, this study had some limitations. First, it had a small sample size of 621 patients, which may not have provided sufficient statistical evidence to prove the role of p16INK4a in USMTs. Studies related to the survival data for USMTs are scarce. Second, to a certain extent, the treatment for each patient varied, depending on the particular clinical manifestations, which should not be ignored. Third, the lack of a standardized immunostaining point of cut-off for positive p16INK4a expression may have led to inaccurate results and variations in different studies. For these reasons, more large-scale studies and a greater body of evidence are needed to investigate p16INK4a expression in USMTs.

In conclusion, despite its limitations, the present meta-analysis suggests that overexpressed p16INK4a correlates significantly with LMS and LM variants compared with LM, and there is a higher level of p16INK4a expression in LMS than in LM variants. The assessment of p16INK4a expression is capable of providing better diagnostic information for patients with USMTs. Further studies are needed to verify this conclusion and to identify the prognostic value of p16INK4a expression in USMTs.

Conflicts of interest

The authors declare no conflict of interests.

REFERENCES


p16INK4a and uterine smooth muscle tumors


